1.0002
price up icon0.61%   0.00605
 
loading
Rallybio Corp stock is traded at $1.0002, with a volume of 5,619. It is up +0.61% in the last 24 hours and down -9.08% over the past month. Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
See More
Previous Close:
$0.9941
Open:
$1
24h Volume:
5,619
Relative Volume:
0.08
Market Cap:
$41.39M
Revenue:
-
Net Income/Loss:
$-74.56M
P/E Ratio:
-0.5125
EPS:
-1.9516
Net Cash Flow:
$-60.27M
1W Performance:
-0.98%
1M Performance:
-9.08%
6M Performance:
-37.88%
1Y Performance:
-58.33%
1-Day Range:
Value
$0.9803
$1.0221
1-Week Range:
Value
$0.95
$1.0221
52-Week Range:
Value
$0.95
$3.46

Rallybio Corp Stock (RLYB) Company Profile

Name
Name
Rallybio Corp
Name
Phone
203- 859-3820
Name
Address
234 CHURCH STREET, NEW HAVEN
Name
Employee
25
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
RLYB's Discussions on Twitter

Compare RLYB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
RLYB 0.9803 41.39M 0 -74.56M -60.27M -1.9516
VRTX 447.95 115.74B 10.63B -479.80M -1.35B 13.33
REGN 746.58 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 590.60 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.33 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.59 24.49B 3.30B -501.07M 1.03B 11.54

Rallybio Corp Stock (RLYB) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-17-23 Initiated H.C. Wainwright Buy
Apr-10-23 Initiated Wedbush Outperform
Dec-09-22 Initiated JP Morgan Overweight
Feb-22-22 Initiated JMP Securities Mkt Outperform
Aug-23-21 Initiated Cowen Outperform
Aug-23-21 Initiated Evercore ISI Outperform
Aug-23-21 Initiated Jefferies Buy
View All

Rallybio Corp Stock (RLYB) Latest News

pulisher
08:00 AM

Rallybio Launches Phase 2 Trial for Groundbreaking Pregnancy Treatment RLYB212 | RLYB Stock News - StockTitan

08:00 AM
pulisher
Nov 15, 2024

Rallybio stock hits 52-week low at $0.96 amid market challenges - Investing.com India

Nov 15, 2024
pulisher
Nov 12, 2024

FMR LLC Acquires Shares in Rallybio Corp - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

HC Wainwright Issues Pessimistic Forecast for Rallybio (NASDAQ:RLYB) Stock Price - Defense World

Nov 12, 2024
pulisher
Nov 08, 2024

Staff cuts help New Haven-based biotech Rallybio reduce 3Q loss - Hartford Business Journal

Nov 08, 2024
pulisher
Nov 07, 2024

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates - BioSpace

Nov 07, 2024
pulisher
Nov 07, 2024

Rallybio Narrows Losses 37%, Advances RLYB212 Trial with $75M Cash Runway | RLYB Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 05, 2024

Two former Alexion leaders fight through a tough market to maintain a rare disease biotech - PharmaVoice

Nov 05, 2024
pulisher
Oct 30, 2024

Rallybio stock plunges to 52-week low at $0.99 amid market challenges - Investing.com Canada

Oct 30, 2024
pulisher
Oct 30, 2024

Rallybio advances novel FNAIT prevention trial By Investing.com - Investing.com Canada

Oct 30, 2024
pulisher
Oct 29, 2024

Rallybio advances novel FNAIT prevention trial - Investing.com India

Oct 29, 2024
pulisher
Oct 29, 2024

Rallybio stock plunges to 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa

Oct 29, 2024
pulisher
Oct 29, 2024

Rallybio’s trial applications of RLYB212 in pregnant women with FNAIT approved - TipRanks

Oct 29, 2024
pulisher
Oct 29, 2024

Rallybio to Begin First Clinical Trial for Prevention of Rare Pregnancy Blood Disorder - Femtech Insider

Oct 29, 2024
pulisher
Oct 29, 2024

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT - Business Wire

Oct 29, 2024
pulisher
Oct 23, 2024

Rallybio stock hits 52-week low at $1.08 amid market challenges - Investing.com Australia

Oct 23, 2024
pulisher
Oct 14, 2024

Rallybio stock plunges to 52-week low at $1.08 amid market challenges - Investing.com

Oct 14, 2024
pulisher
Oct 01, 2024

Rallybio shares hold Buy rating on HPP treatment data - Investing.com India

Oct 01, 2024
pulisher
Sep 30, 2024

Rallybio's SWOT analysis: FNAIT treatment stock poised for growth amid challenges - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting - StockTitan

Sep 30, 2024
pulisher
Sep 24, 2024

Rallybio reveals higher FNAIT risk across populations By Investing.com - Investing.com Australia

Sep 24, 2024
pulisher
Sep 23, 2024

Rallybio reveals higher FNAIT risk across populations - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting - Business Wire

Sep 23, 2024
pulisher
Sep 19, 2024

Rallybio Co. (NASDAQ:RLYB) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Rallybio announces board member resignation - Investing.com

Sep 18, 2024
pulisher
Sep 17, 2024

Rallybio announces board member resignation By Investing.com - Investing.com UK

Sep 17, 2024
pulisher
Sep 17, 2024

Dr. Kush Parmar Steps Down from Rallybio’s Board and Committee - TipRanks

Sep 17, 2024
pulisher
Sep 17, 2024

Rallybio Corporation Announces Resignation of Kush Parmar as Member of Board and Chair of Nominating and Corporate Governance Committee, Effective October 31, 2024 - Marketscreener.com

Sep 17, 2024
pulisher
Sep 12, 2024

RLYBRallybio Corporation Latest Stock News & Market Updates - StockTitan

Sep 12, 2024
pulisher
Sep 10, 2024

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit - Business Wire

Sep 10, 2024
pulisher
Sep 09, 2024

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree - Business Wire

Sep 09, 2024
pulisher
Sep 09, 2024

Rallybio - FiercePharma

Sep 09, 2024
pulisher
Sep 04, 2024

Rallybio stock plunges to 52-week low, hits $1.09 - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Rallybio (NASDAQ:RLYB) Given “Buy” Rating at HC Wainwright - Defense World

Sep 04, 2024
pulisher
Sep 03, 2024

Rallybio reiterated at Buy at H.C. Wainwright on FNAIT drug data - Investing.com

Sep 03, 2024
pulisher
Aug 29, 2024

Rallybio advances RLYB212 to phase 2 for FNAIT prevention - Investing.com India

Aug 29, 2024
pulisher
Aug 29, 2024

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis - Business Wire

Aug 29, 2024
pulisher
Aug 28, 2024

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully - Simply Wall St

Aug 28, 2024
pulisher
Aug 27, 2024

Rallybio to Present at Upcoming Investor Conferences - Elk Valley Times

Aug 27, 2024
pulisher
Aug 21, 2024

Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Aug 21, 2024
pulisher
Aug 15, 2024

Rallybio stock plunges to 52-week low at $1.09 amid market challenges - Investing.com Australia

Aug 15, 2024

Rallybio Corp Stock (RLYB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):